VEGF is one of the key regulators of angiogenesis, vasculogenesis, and developmental hematopoiesis. It is a mitogen and survival factor for vascular endothelial cells while also promoting vascular endothelial cell and monocyte motility. Binding of growth factors to the ectodomain of their transmembrane receptors leads to receptor dimerization, protein kinase activation, trans-autophosphorylation, and initiation of signaling pathways. The VEGF family of receptors (RTK class IV, VEGF receptor family) consists of three protein–tyrosine kinases (VEGFR1, VEGFR2, and VEGFR3) and two non-protein kinase co-receptors (neuropilin-1 and 2). Targeting VEGF receptors proved to be a successful therapeutic approach for disorders with non-physiologic angiogenesis including age-related macular degeneration of the eye, diabetic retinopathy, rheumatoid arthritis, tumor growth and metastasis1.
 Vascular endothelial growth factor (VEGF) signaling during tumor progression. A comprehensive review of the discovery of the VEGF family of ligands and receptors. R. Roskoski Jr. Crit. Rev. Oncol. Hematol. 2007, 62, 179–213.
 VEGF receptor protein–tyrosine kinases: Structure and regulation. Mini Review. R. Roskoski Jr. Biochem. Biophys. Res. Com. 2008, 375, 287–291.
Items 1 to 15 of 26 total
|Axon ID||Name||Description||From price|
|1638||ABT 869||PDGFR, c-KIT and VEGFR tyrosine kinase inhibitor||€85.00|
|1653||AEE 788||EGFR, ErbB2 and VEGFR tyrosine kinase inhibitor||€95.00|
|1414||AG 013736||PDGFR,c-KIT and VEGFR tyrosine kinase inhibitor||€75.00|
|1768||AMG 706||Multiple receptor tyrosine kinase inhibitor||€105.00|
|1850||BMS 540215||Inhibitor of VEGFR (subtype 2 and 3 selective)||€110.00|
|1864||Brivanib alaninate||Prodrug of BMS 540215; Inhibitor of VEGF||€105.00|
|1819||Cabozantinib S-malate||Inhibitor of multiple receptor tyrosine kinases, specifically MET and VEGFR2||€85.00|
|1461||Cediranib||VEGFR tyrosine kinase inhibitor||€70.00|
|1662||CP 547632||VEGFR2 tyrosine kinase inhibitor||€99.00|
|1942||E 3810 dihydrochloride||Dual VEGFR/FGFR tyrosine kinase inhibitor||€95.00|
|1959||Golvatinib||Potent and orally available inhibitor of c-MET (HGFR) and VEGFR2||€95.00|
|1420||GW 786034||PDGFR, c-KIT and VEGFR tyrosine kinase inhibitor||€70.00|
|1963||LY 573636||Anti-tumor agent; causes growth arrest and apoptosis||€95.00|
|2648||Nintedanib||RTK inhibitor with antiangiogenic and antineoplastic activities||€75.00|
|1547||OSI 930||c-Kit and VEGFR2 tyrosine kinase inhibitor||€90.00|